← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Ridgeline Therapeutics, Llc
Houston, TX
$6,774,708
Total funding
6
Grants
Funding over time
peak $1.8M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,774,708 · 6
By mechanism
U44$4,202,826 · 1
R44$1,339,717 · 1
R41$909,733 · 3
R43$322,432 · 1
Investigators at Ridgeline Therapeutics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Preclinical validation of a novel adjunct small molecule drug to prevent muscle loss and enhance weight loss in older adults$1,339,717
R44 · FY2025 · AG
Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture$1,246,866
U44 · FY2022 · AG
Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture$1,242,959
U44 · FY2023 · AG
Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture$1,229,027
U44 · FY2021 · AG
Dose-ranging safety and efficacy studies to advance novel mechanism-of-action drug candidates to reverse age-related muscle degeneration$357,630
R41 · FY2018 · AG
A Novel Small Molecule Oral Therapeutic to Prevent and Reverse Skeletal Muscle Atrophy in Aging Adults$322,432
R43 · FY2023 · AG
Dose-ranging safety and efficacy studies to advance novel mechanism-of-action small molecule leads to treat obesity-linked type 2 diabetes$299,972
R41 · FY2018 · DK
Preclinical studies to validate the efficacy of novel mechanism-of-action small molecule inhibitors to treat Duchenne muscular dystrophy$252,131
R41 · FY2019 · AR
Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture$247,436
U44 · FY2023 · AG
Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture$236,538
U44 · FY2024 · AG